Trial Profile
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane
- Indications Advanced breast cancer; Bone metastases; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms BOLERO-2
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 22 Sep 2020 Results from NCT00073528 (n=484) and NCT00863655 (n=261 ) developing prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic HER2-negative breast cancer, published in the Clinical Cancer Research
- 31 May 2020 Results (n=510) assessing the prognostic/predictive ability of serum biomarker, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 09 Dec 2017 Results assessing the prognostic and predictive ability of activin A (n=513) presented at the 40th Annual San Antonio Breast Cancer Symposium